Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.84
-0.0200-0.52%
Post-market: 3.840.00000.00%19:47 EDT
Volume:786.21K
Turnover:3.01M
Market Cap:120.15M
PE:-0.93
High:3.90
Open:3.90
Low:3.75
Close:3.86
52wk High:50.40
52wk Low:3.60
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.97
T/O Rate:4.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.55
PE(LYR):-1.35

Loading ...

Chimeric Therapeutics Suspended as It Negotiates Creditor Deals and Board Restructure

TIPRANKS
·
1 hour ago

Have Insiders Sold Cutia Therapeutics Shares Recently?

Simply Wall St.
·
4 hours ago

TScan Therapeutics Announces Executive Departures Amid Reorganization

TIPRANKS
·
5 hours ago

Outlook Therapeutics Faces Nasdaq Minimum Bid Price Deficiency

TIPRANKS
·
6 hours ago

Halozyme Therapeutics Adds James Daly to Board

TIPRANKS
·
6 hours ago

Analyst Reiterates Buy on Quince Therapeutics, Maintaining Unchanged $98 Price Target Amid Advancing Pulmonary Pipeline

TIPRANKS
·
6 hours ago

Whitehawk Therapeutics initiated with a Buy at Stifel

TIPRANKS
·
7 hours ago

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

GlobeNewswire
·
7 hours ago

Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk

GlobeNewswire
·
7 hours ago

Sarepta Therapeutics is Maintained at Neutral by JP Morgan

Dow Jones
·
9 hours ago

EPIRUS Therapeutics: Buy Rating Reiterated on EP-104GI’s Emerging Clinical Profile and Upcoming Phase 2b Catalyst; $16 Price Target Unchanged

TIPRANKS
·
9 hours ago

Keros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in Play

TIPRANKS
·
10 hours ago

Damora Therapeutics Advances CALR-Targeted Antibody Into Early Clinical Testing

TIPRANKS
·
10 hours ago

CytoMed Therapeutics Posts Narrower Interim Loss in June 2026 SEC Filing

TIPRANKS
·
Yesterday

Indaptus Therapeutics Extends Timeline for Private Placement Financing

TIPRANKS
·
Yesterday

Silexion Therapeutics Begins Global SIL204 Pancreatic Cancer Trial

TIPRANKS
·
Yesterday

Cutia Therapeutics to Launch Up to 30 Million Yuan Share Buyback

MT Newswires Live
·
Yesterday

Cutia Therapeutics Unveils Targeted Share Buyback to Signal Confidence

TIPRANKS
·
Yesterday

Thalia Therapeutics Accelerates RNA Strategy With Sanmirna Deal and Clinical-Stage Pipeline

TIPRANKS
·
Yesterday

Shield Therapeutics updates total voting rights and share capital

TIPRANKS
·
Yesterday